Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 6/20 | 0.39 |
| ▸ | ACHE | P22303 | 6/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL61190 | 0.91 | HTR2C (0.40) | HTR2CHTTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL62744 | 0.82 | BCHE (0.41) | HTTSMN1; SMN2ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL62161 | 0.82 | C5AR1 (0.40) | HTR2CHTTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL63584 | 0.81 | BCHE (0.42) | HTTALDH1A1L3MBTL1BCHEACHE | |
| SCHEMBL63161 | 0.79 | ACHE (0.43) | HTTSMN1; SMN2ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL63671 | 0.76 | ACHE (0.41) | HTTSMN1; SMN2ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL63459 | 0.74 | C5AR1 (0.39) | HTTSMN1; SMN2ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL61728 | 0.74 | C5AR1 (0.39) | HTTSMN1; SMN2ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL62829 | 0.71 | C5AR1 (0.39) | HTTSMN1; SMN2ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL62925 | 0.71 | C5AR1 (0.43) | HTTSMN1; SMN2ALDH1A1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-01-28 | — | — | US | disclosed |
| US-7482350-B2 | 4,5-disubstituted-2-aryl pyrimidines | NEUROGEN CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482350-B2 | 4,5-disubstituted-2-aryl pyrimidines | NEUROGEN CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | C5AR2, C5AR1, C3AR1 | HTR2C 220/4885HTT 4501/4885SMN1; SMN2 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.